Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
| Author | |
|---|---|
| Abstract |
:
Binge-eating disorder (BED), the most prevalent eating disorder, is associated strongly with obesity and functional impairments. Few evidence-based treatments for BED exist; a pharmacotherapy effective in reducing both binge eating and weight needs to be identified. This placebo-controlled double-blind pilot RCT evaluated the acute effects of naltrexone + bupropion (NB) on BED with obesity and examined the longer-term effects through 6-month follow-up after the discontinuation of medication. |
| Year of Publication |
:
2021
|
| Journal |
:
Clinical therapeutics
|
| Volume |
:
43
|
| Issue |
:
1
|
| Number of Pages |
:
112-122.e1
|
| ISSN Number |
:
0149-2918
|
| URL |
:
https://linkinghub.elsevier.com/retrieve/pii/S0149-2918(20)30478-1
|
| DOI |
:
10.1016/j.clinthera.2020.10.010
|
| Short Title |
:
Clin Ther
|
| Download citation |
